marketing, Thanks, capabilities, outlined map for engagement, facilities XXXX, company road stakeholder an including ago, aggressive sales financial identity, spanning our Ryan. One position. corporate year the and objectives and and finally,
capable objectives, CDMO. these and and the corporate sales, stronger year, first impacting company’s executed more strategic identity. achievements successfully the we I a creating will During on marketing address
legacy solid-dose represent within company strategies products, best market commercial commercial who clients serve engage: our each During transfers; a of designed segment which as development our of sales to finally, and profit-sharing growing products, three Verapamil; the such segments XXXX, the discrete oral the tech including adopted we early-stage business.
distinct. best inventory, and sales et and clients, supply from mature and range considerably different to industry-related economic commercially are such, our infrastructure. customer support support businesses the to chain, to development customer customer order are segment regarding market their between and Considerations our early-stage too outsourcing, in be so factors strategies and from impacting Our should cetera, decisions as
of for and project end, Societal drivers sales key decision-making clients. as during such important relationships this our processes, segment-specific a product that life and the management, productive factors, approach cycle with metrics accounts To XXXX, and success, approach creating different to employed
Societal during changed our the Science to Pharma tagline to a the marketing As name Bringing and and XXXX, evolved adopted sales its complement Society. Recro from company approach, to CDMO
to this contributed sales identity, our These steps the efforts, our growing which to patients we clinical underway believe company’s people, with services our the with our operate, all, and We sales serve. the commitment hand-in-hand XXXX our and corporate of trial the marketing prior to in to XX% approach strong new in compared and communities the ultimately customers, we that transformation bespoke is year. strategic business most signals
two the ended number we year with had of that expanded diversified than X we customers ago. Importantly, with XXXX just customer to more and base compared significantly years times a the
of rate year. new our throughout best to and year contributed win deployment the processes the business through threefold practices Our robust sales increasing
our by amongst scope programs we base. signed projects potential XXXX, new or customers. customer During we XX added new with expanded customers and ignore new changes the our or the year, success challenges XXX Combined, presented Despite signed our market for cannot current environment. different we XX over during XX
In long limited opportunity as are as today’s to have facing to raise capital of are money or funding in many XX% possible. more the It traded estimated market-dependent biopharma low companies taking near-term. negative that preserve biotech enterprise than challenges measures and been publicly cash companies with therefore their market, has values
number It timing of and cash. surprise are production by restraints has cash preserve a development And employing CDMOs strategies inventory, that impacting current that and of customer regarding decisions no prioritization. customers’ are been is to companies these many reported it
the to circumstances trial XXXX there delay believe such manufacturing We for impact year services. during should and to our clinical customers potential development business decide is
in Given conditions. reorienting to the change our is efforts team Societal proactively market our development environment, meet best this operating these business
business are currently team new this our to working focus, and development with optimizing approximately have repositioned to client recently they the singularly expand established of we that clients. those we part XX business so certain As relationships dedicated have of
injectables with full on personnel the market the to relatively take the new hired advantage West of important we this also have offering opportunities We in in new have and Coast. expertise
We us better targeting new our assist in business. market enhanced to intelligence effort have
spectrum and these to produced visitors for through high-potency and want all are increasingly software seen formulations in good the tech extended-release products; programs growth offerings; commercial such marketing fill/finish tools common of preclinical investing website. for and we solid-dose Combined, our lyophilization; dosage future second-source create and finally, the transfers our and moves and established; oral client have as U.S. relevant expertise curated a experience production; tablets, new labeling where and create oral as And commercial both immediate way to sites solid-dose which as programs with packaging, we clients capsules distribution. other development molecule business gels customers small films; the our both and their forms from for in and experience a across current
on, these XXXX, we’re and operate general moving very a XXXX, if sales as market during continue cannot results the branding company still stand several had see strong years. the pleased to year. to that the reiterate work our the best with marketing we we than our adjustments But I’d and in Before of sales, like in succeed from and much position the all past haven’t different conditions which in to to I’m sales us backdrop excited approach financial feel changed. to
I’ll now business: another our capabilities. and important breadth facilities shift discuss new the our gears contributor attracting to state-of-the-art of to
aseptic lyophilization services. XXXX, new and During we launched fill/finish our
filling allow are biologics. to and will continue different our to In clients, order we and us entirely an expertise now provide our of to subset lyophilization of prepared are we announce support pleased market. to capabilities that to access This expand our better
and The explore we’ll of for expansion facilities and opportunities the to demand, continue company growth continues enhancement to our market through customer and evaluate capabilities.
the and made core pillars brick investments pleased two key groups with report in and that we XXXX, our are these mortar, two of important these for represented goals company’s successfully stakeholder of to Societal substantial relations milestones. business, are we employees. customers our Beyond and meeting Strengthening our our
While service oral of a enhancements we internal for tech new the also implemented of experience, our transfer introduced improve customers. to key the Societal process customer launch solid-dose XX-XX our number second-source commercial
elevated reflects and is associated the risks model supply our implementing second-source team Our with ultimately, that to industry. suppliers program team strategies new business. our significantly that pharmaceutical way overall pipeline service This relationships, our and response and of chain created has the new the strengthen the this importance global our the in vulnerabilities within new growing exploring to
And product everywhere to exceptional, the every supporting consistently standards. delivering we’re our to regulatory drive while quality industry highest From our between, the employees and on-time about to equally employing that of customers passionate high-quality Societal’s our business. are growth, delivery in is aspect team critical while
prioritize During time to exceedingly we talent essential a retention. believe when staffing difficult, is it is
To growth to not committed our employees that professionalism work to but to end, has culture Societal support, only that thrive. of allows and a
This organization, in by and growth people States. in working importantly, for culture was sponsored recognized educational based this XXXX, our personal across certified United an the we’re efforts the built is company have The team, entirely to say was expanded Great prestigious of validated CDMO interest and Societal current During Work created most facilitated forums, way. and on and employees professional events award cultural address very their XXXX, our opportunity the pleased business. Place effort and what the to the in about experience to at November Societal,
executed we successful company’s multiple as of were sheet multistep the all XXXX year, our strengthen structure, capital The perhaps most we proud While concurrent the financial our are and successfully our achievement our a to was balance overall during strategy accomplishments during impactful of transactions recast designed execution profile. improve the follows.
our debt outstanding strengthen the the XXX close national the unused we sales of the agreement adjacent further debt down a leverage facility proceeds in Societal’s located $X.X a we to approximately our XXXX. will half expect from homebuilder Gainesville, land to and August intend diligence, to approximately in completion sale more by expectation lakefront sale XXXX, we leading be below to First, to million. sheet of the land paying sell is acres that balance second purchase Georgia. of manufacturing The use our to in for signed Subject And with X.X. net to of ratio
San million non-dilutive high-potency Tenet impact facility with site a this manufacturing XXXX, Equity with Gainesville, and Gainesville, proceeds. and Second, Diego, transaction in CDMO’s This Equity, lyophilization and Georgia our Societal Through sterile CDMO clinical not fill/finish Societal in in multiple December yielded other Tenet renewal and options. agreement sale entered its campus development, facilities, California. site does transaction lease its in agreement, which and also packaging a gross with vial including located and $XX development XX-year leaseback into we Georgia executed for
offerings The stock closing underwriting preferred expenses. and deducting gross with third common approximately December proceeds offering to $XX.X company of million the discount the stock, public XXXX and step concurrent prior of also occurred in generating estimated
we a of from Bank the of Canada. December maturity interest of debt overnight these Royal significantly December a at plus finally, debt $XX.X approximately were The XX% or which the carried of three-year base is new annum. of And facility the improved date XXXX, company. million facility in term the per bearing secured interest new previous A rate held initial secured near-term for form X.X% for transformational floating the in The Combined, financing rate, company’s loan facility of XX, an an terms the credit of with a rate transactions and facility terms XXXX. Athyrium, SOFR,
and company advantageous a able it Athyrium Bank and term interest the CDMO maturity million terms areas with leverage, year-end, Canada to loan its that Societal debt to with to Prior that Royal are $XXX obligation. retire was repay A $XX.X debt carries the in facility more date of with significantly and million of replace
to In times significantly burden annually. over leverage reducing annual X company’s the EBITDA, greater addition to increase debt to company’s X the with approximately these our estimated interest million by ratio $X net reducing helped immediately total to times million debt, that just an improve EBITDA from than number the transactions potential $X
will with year. $X.X be is expect our strengthened expected the position this generate later We which million to the proceeds sale, of of closing that further financial land
as began XXXX seeing requiring in better our for a small successful development And From of compounds we an strength We support molecules expertise which in perspective, in expertise By opportunities, are market set result, with with a as to achieved. of advantages. puts we including both of multiple growing all oral areas. position any have standard, a key XXXX was complex goals, out a formulation were and highly aggressive Societal. and of set productive these a year number with of we added us solids biologics. injectables And
capacity is and supply chain as have U.S., geopolitical which customer the strategically our currently in advantageous We navigates base the headwinds.
We execution changing motivated record to operational with needs highly have agility CDMO of of a and work the experienced a and customers. the success track team,
impacted larger reported chain have delivery the challenges. been recent supply of times CDMOs Some that their have by
and continues reliability supply stability contrary, to Societal future us diversify cost-efficient needs the to allowed customers, manner. anticipate our provide a our innovative And expand On customer to has and so and growing reputation steps base. the our security in take of and do
end XXXX, As times of more X an expansion client of from exciting the orders two growing number customers we Societal had years win opportunity ago, the had than business of creating new and to base. our only
began of sheet. our financial our of with we of successful cleanup XXXX heels renewed a position the on balance Finally, strength
of reasons, all great For we look these with ahead optimism.
and For projecting of of an are and million year $XXX $XX we the million. $XX million between and full million XXXX, $XX EBITDA revenue between
my This concludes remarks up questions. today. open now for prepared Operator? the We call can for
